Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Helichrysum arenarium, commonly known as sandy everlasting, is a botanical extract from the Asteraceae family traditionally utilized in European ethnomedicine for its choleretic and cholagogue properties. It is primarily indicated for the treatment of dyspeptic disorders and has been evaluated in clinical trials for its potential to reverse traits of metabolic syndrome, including hypercholesterolemia and hyperglycemia. The extract is rich in polyphenols, specifically flavonoids such as naringenin and apigenin, which contribute to its anti-inflammatory and antioxidant activities. Mechanistically, H. arenarium infusions modulate the gut microbiota composition, acting as a prebiotic to reduce the abundance of Firmicutes and Proteobacteria, and decrease systemic inflammatory markers like interleukin-1 beta (IL-1β). Clinical evidence suggests it effectively reduces total and LDL cholesterol levels, likely through the stimulation of bile acid secretion and subsequent de novo synthesis from serum cholesterol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Helichrysum arenarium.